Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

427
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
427
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

386
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
386
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A.

Blood·2022
Same author

Genetic regulation of plasma von Willebrand factor levels in health and disease.

Journal of thrombosis and haemostasis : JTH·2018
Same author

The Jamaican Haemophilia Registry: Describing the burden of disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

World bleeding disorders registry: The pilot study.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Early cellular interactions and immune transcriptome profiles in human factor VIII-exposed hemophilia A mice.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Minimal dataset for post-registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2017

Related Experiment Video

Updated: Mar 3, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.7K

Factor VIII inhibitors: Advances in basic and translational science.

J D Lai1, D Lillicrap1

  • 1Department of Pathology & Molecular Medicine, Queen's University, Kingston, ON, Canada.

International Journal of Laboratory Hematology
|April 28, 2017
PubMed
Summary

Developing inhibitors against factor VIII (FVIII) is a major concern in hemophilia A treatment. New immunological insights offer hope for predicting inhibitor development and improving immune tolerance induction protocols.

Keywords:
B cellsT cellsantigen-presenting cellsfactor VIIIhemophilia Aimmunityinhibitorstolerance

More Related Videos

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.8K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K

Related Experiment Videos

Last Updated: Mar 3, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.7K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.8K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K

Area of Science:

  • Hematology
  • Immunology
  • Translational Medicine

Background:

  • The development of factor VIII (FVIII) inhibitors affects 20%-30% of hemophilia A patients.
  • Immune tolerance induction (ITI) is effective in ~75% of patients but poses significant burdens.
  • Predicting inhibitor development and optimizing ITI protocols remain critical unmet needs.

Purpose of the Study:

  • To review recent advances in the fundamental immunology of FVIII inhibitors.
  • To explore how these immunological findings can inform translational medicine for hemophilia A treatment.

Main Methods:

  • Review of current literature on FVIII inhibitor immunology.
  • Analysis of emerging research on predictive factors and therapeutic strategies.
  • Discussion of the implications for clinical practice and future research.

Main Results:

  • Significant progress has been made in understanding the immunological mechanisms underlying inhibitor development.
  • New insights highlight potential biomarkers for predicting inhibitor risk.
  • Emerging data suggest novel approaches to enhance the efficacy and reduce the burden of ITI.

Conclusions:

  • Advances in immunology are paving the way for more personalized and effective strategies in hemophilia A management.
  • Translational research is crucial for developing predictive tools and optimized ITI protocols.
  • Future directions include leveraging immunological knowledge to improve patient outcomes and reduce treatment-related burdens.